16 results about "Amyrin" patented technology

This invention discloses a composition and method comprising bis(demethoxycurcumin) enriched in at least 20% w / w for inhibiting receptor for advanced glycation end products (RAGE) expression in subjects with chronic inflammatory conditions. The composition further comprises β-amyrin palmitate (BAP). This invention also discloses the use of the above composition in controlling chronic inflammatory conditions in subjects.

The application provides a camellia oil adulteration identification method and system, which comprises the following steps: obtaining the content of oleic acid, beta-amyrin and campesterol in the camellia oil to be identified; determining whether the content of oleic acid is greater than a first threshold value; if yes, determining that the camellia oil to be identified is a mixture of one or more of camellia oil, high-oleic peanut oil, high-oleic sunflower oil and high-oleic rapeseed oil; if no, determining that the camellia oil to be identified is a mixture of one or more of peanut oil and soybean oil; then determining whether the content of beta-amyrin causes the displacement amount of the clustering result of the corresponding camellia oil to be less than a second threshold value; if yes, determining that the camellia oil to be identified is not adulterated camellia oil; if no, determining that the camellia oil to be identified is adulterated oil; then determining whether the content of campesterol causes the displacement amount of the clustering result of the corresponding high-oleic rapeseed oil to be less than a third threshold value, and determining whether the camellia oil to be identified is camellia oil adulterated with high-oleic rapeseed oil.

The invention relates to the field of bioengineering and technology, in particular to an engineering bacterium for synthesizing isoglycyrrhetinic acid, a construction method of the engineering bacterium and a method for synthesizing the isoglycyrrhetinic acid by using the engineering bacterium. The engineering bacterium comprises introduced exogenous genes, the exogenous genes comprise an HMG-CoA reductase gene, a beta-amyrin synthase gene, a beta-amyrin C-11 oxidase coding gene, a P450 reductase gene, a 11-O-beta-amyrin C-29 oxidase coding gene and an expression-enhanced endogenous gene, and the expression-enhanced endogenous gene is a beta-amyrin synthase gene, a beta-amyrin C-11 oxidase coding gene and a P450 reductase gene. Wherein the endogenous genes comprise squalene oxidase coding genes, the endogenous genes GAL80, HO and BTS1 in the engineering bacteria are knocked out, and the starting strain of the engineering bacteria is saccharomyces cerevisiae. According to the engineering bacterium provided by the embodiment of the invention, isoglycyrrhetinic acid can be obtained in an efficient, green and sustainable production mode.

This invention discloses a method for improving the yield of D-amyglucosinolates in peach kernels, belonging to the field of natural product extraction technology. Existing stepwise enzyme inactivation and defatting processes suffer from drawbacks such as cumbersome procedures and the easy isomerization of D-amyglucosinolates to L-amyglucosinolates. This invention involves pressing peach kernels at 100–150°C, completing enzyme inactivation and defatting in a single step. The resulting residue is then extracted with a 60–70 vt% ethanol aqueous solution at 70–90°C for 0.2–1 hour, repeated 1–3 times. This method overcomes the technical bias of high-temperature-induced D-amyglucosinolate isomerization, achieving a synergistic effect through the instantaneous coupling of high temperature and pressing. The extraction transfer rate of D-amyglucosinolate is no less than 81%, and the extraction transfer rate of L-amyglucosinolate is no more than 10%, with a D / L ratio greater than 15:1. This simplifies the process while achieving highly selective extraction of D-amyglucosinolates.

The invention discloses new application of alpha-amyrin, namely application of alpha-amyrin in preparation of a medicine for treating schizophrenia, experimental results show that alpha-amyrin can effectively relieve MK-801 induced schizophrenia symptoms of mice, reduce HT22 cytotoxicity induced by glutamic acid, and can be used for preparing medicines for treating schizophrenia. The evidences show that the alpha-amyrin can improve the symptoms of schizophrenia.

The invention relates to an euphorbia lactuca triterpenoid synthase EhypOSC2 gene and application thereof, and belongs to the technical field of biology. The nucleotide sequence of the euonymus japonicus triterpenoid synthase EhypOSC2 gene is as shown in SEQ D NO.1, and the total length of the sequence is 2277 bp; the amino acid sequence of the encoded protein is shown as SEQ ID NO.2, and 758 amino acid residues are encoded. The euonymus japonicus triterpenoid synthase EhypOSC2 gene can be used as a biosynthesis regulation gene of beta-amyrin and lupeol and is applied to preparation of beta-amyrin, and the lupeol has a remarkable application prospect and is easy to popularize and apply.

The invention discloses an active composition for treating atopic dermatitis and application thereof, and belongs to the technical field of biological medicine. The (+)-catechin hydrate, the epicatechin, the chlorogenic acid and the amyrin in a specific proportion are compounded to serve as active ingredients, the multi-target and multi-channel synergistic interaction effect is achieved, and the effect of remarkably treating atopic dermatitis is achieved; besides, the components of the carrier are optimized, the stability, skin permeability and slow release performance of the active components are remarkably improved, percutaneous penetration and target site accumulation of the active components are enhanced, and therefore the local drug concentration and the curative effect durability are improved; the composition has the advantages that the composition can be rapidly formed at low temperature, the biological activity of the active ingredients is better, the composition can be processed and prepared into various local external dosage forms such as gel, cream, dressing and spray according to clinical requirements, the application is flexible, the adverse reaction possibly caused by long-term use of traditional hormone or chemical synthetic drugs is avoided, and the composition has a good industrial conversion prospect.

This invention provides a CYP716 gene, protein, and applications for catalyzing the oxidation of β-amyrin at the C22α and C28 positions, belonging to the field of biotechnology. The CYP716 gene includes either CYP716BX1 (nucleotide sequence as shown in SEQ ID No. 1) or CYP716BX2 (nucleotide sequence as shown in SEQ ID No. 2). Studies have shown that CYP716BX1 and CYP716BX2 are isoenzymes, both capable of catalyzing the oxidation of β-amyrin at the C22α and C28 positions to 22α-hydroxy-kapogonadiol or 22α-hydroxy-oleanolic acid, and also capable of catalyzing the oxidation of 21β-hydroxy-β-amyrin at the C22α and C28 positions to 21β,22α-dihydroxy-kapogonadiol. This invention can provide key gene elements for the synthetic biology research of cyrimyl alcohol-type triterpenoids.

The invention discloses a pharmaceutical composition for treating and / or preventing depression, and belongs to the technical field of biological medicines. The technical problem to be solved is to significantly improve depression-like behaviors and protect nerve cells, and has an obvious effect on treatment and / or prevention of depression. According to the key point of the technical scheme, the pharmaceutical composition for treating and / or preventing depression comprises a secoiridoid glycoside compound, a xanthone glycoside compound and a beta-amyrin type pentacyclic triterpenoid compound in a mass ratio of 1: (0.25-6): (0.1-5), and one or more medically acceptable auxiliary materials.

This invention relates to methods of producing triterpenoids using one or more of (i) Saponaria officinalis β-amyrin synthase (SobAS) (ii) S. officinalis C28 oxidase (SoC28) (iii) S. officinalis C28C16 oxidase (SoC28C16)(iv) S. officinalis C23 oxidase (SoC23); (v) S. officinalis QA 3-O glucuronosyl transferase SoCSL; (vi) S. officinalis QA-GlcA SoC3Gal; (vii) S. officinalis QA-GlcA-Gal x SoC3Xy; (vii) S. officinalis QA-Tri fucosyl transferase SoC28Fu (ix) S. officinalis QA-TriF rhamnosyl transferase SoC28Rha (x) S. officinalis QA-TriFR xyl SoC28Xul1; (xi) S. officinalis QA-TriFRX xyl SoC28Xyl2; (xii) S. officinalis QA-TriFRXX quinovosyl SoGH1 and (xiii) A. officinalis QA-TroF(Q)RXX acetyl SoBAHD1 polypeptide. Methods, host cells, isolated polypeptides, nucleic acids, and plants are provided.

The invention belongs to the technical field of edible oil processing, and particularly relates to camellia oleifera seed oil with high content of beta-amyrin and a preparation method thereof, and the preparation method comprises the following steps: 1) freshly squeezing camellia oleifera seed crude oil from fresh fruits; (2) preparing the camellia oleifera shell biochar; (3) co-doping calcium and phosphorus with the camellia oleifera shell biochar; 4) adsorption treatment; 5) washing and drying; 6) decoloring; (7) deodorizing; and 8) filtering to obtain the camellia oleosa seed oil with high content of beta-amyrin. The method is simple in process, the acid value and the phospholipid content of refined oil can be effectively reduced, the refining time is shortened, the refining cost is reduced, the quality stability of a camellia oleosa seed oil product is ensured, meanwhile, the content of beta-amyrin in the camellia oleosa seed oil can be effectively increased, and therefore the oxidation resistance of the finished camellia oleosa seed oil is improved.

The present invention provides a cytochrome P450 oxidase gene and application of Bupleurum chinense, which is CYP716A41. The enzyme has been confirmed by catalytic experiments to have the function of catalyzing the biosynthesis intermediate of saikosaponin β-amyrin and producing erythrodiol and oleanolic acid in its C-28 multi-step oxidation. The present invention has achieved the heterologous production of erythrodiol, an intermediate in the synthesis of saikosaponin, by using the enzyme, and erythrodiol is an important synthetic intermediate of various C-28 hydroxylated oleanane-type saikosaponins and other C-28 hydroxylated site triterpenoids. The present invention further promotes the analysis of the biosynthetic pathway of saikosaponins and synthetic biology research, and has important research value for the synthesis and regulation of oleanane-type pentacyclic triterpenoids such as saikosaponins and the breeding of Bupleurum plants.

The invention provides a conyza blinii extract (tablet) fingerprint spectrum detection method, which comprises: A) taking a test sample raw material, and pre-treating to obtain a liquid to be detected; the pretreatment mode comprises solvent dissolution and extraction; b) measuring the liquid to be measured by adopting a high performance liquid chromatography-evaporative light scattering method to obtain an HPLC-ELSD (High Performance Liquid Chromatography-Evaporative Light Scattering Detector) fingerprint spectrum of the Conyza blinii extract (tablet); chromatographic conditions of the high performance liquid chromatography are as follows: a chromatographic column is a C18 column; a mobile phase A is an acetonitrile solution, a mobile phase B is a 0.1% formic acid aqueous solution, and gradient elution is carried out; according to the method, a high performance liquid chromatography-evaporative light scattering method is adopted, an acetonitrile-0. 1% formic acid aqueous solution is selected as a mobile phase for gradient elution, ursolic acid, oleanolic acid, beta-amyrin, alpha-amyrin and friedelin are taken as reference substances, and the conyza blinii extract (tablet) fingerprint detection method is established. The scientificity and the internal quality of the conyza blinii extract (tablet) are integrally evaluated.

The present application belongs to the field of bioengineering, and particularly relates to a kind of recombinant yeast and its construction method, the supernatant protein factor derived from southern Peromyscus, Homo sapiens and / or Gallus gallus is expressed in the recombinant yeast, squalene monooxygenase, phospholipid synthesis transcription factor, and / or product synthase (especially beta-amyrin synthase, ergosterol synthase and / or lanosterol synthase), the recombinant yeast can efficiently synthesize triterpenoid compounds (especially squalene, beta-amyrin) and / or sterol compounds (especially ergosterol and / or lanosterol).